Introduction
============

Overall, survival and local control of nasopharyngeal cancer patients have both significantly improved due to advances in diagnostic imaging and the introduction of systemic chemotherapy and intensity-modulated radiotherapy (IMRT), but distant metastasis is still a major cause of treatment failure \[[@b1-roj-2017-00115]-[@b3-roj-2017-00115]\]. Therefore, early identification of patients with a high risk of disease progression before treatment is very important because administration of individualized therapy to these patients may improve their clinical outcome. As current prognostic factors are limited when identifying high-risk patients who require more aggressive treatment \[[@b4-roj-2017-00115]-[@b6-roj-2017-00115]\], newer prognostic factors for clarifying the risk stratification of patients are needed.

Maximum standardized uptake value (SUV~max~) of 2-\[18F\]-fluoro-2-deoxy-D-glucose (^18^F-FDG) positron emission tomography/computed tomography (PET/CT) is an index that reflects tumor metabolism. The clinical significance of a high SUV~max~ has already been identified for many carcinomas such as breast and lung cancer \[[@b7-roj-2017-00115],[@b8-roj-2017-00115]\]. In addition, the findings of several studies have suggested poorer prognosis in nasopharyngeal cancer patients with a higher SUV~max~ \[[@b9-roj-2017-00115]-[@b15-roj-2017-00115]\]. Accordingly, we conducted a study to clarify the prognostic significance of high pre-treatment SUV~max~ and evaluated the significance of the SUV~max~ in both primary site and metastatic nodes.

Materials and Methods
=====================

1. Study patients
-----------------

Between October 2006 and April 2016, 67 nasopharyngeal patients were initially treated with IMRT in two institutions. We retrospectively analyzed these patients' medical records and excluded patients with distant metastasis at the time of diagnosis or who had another malignancy. In addition, patients who had previously received radiotherapy at another hospital and did not complete the planned radiation therapy were excluded. Finally, 53 patients were included in this study that met the following criteria: (1) biopsy-proven nasopharyngeal carcinoma; (2) stage I to IVB according to the American Joint Committee on Cancer (AJCC) staging, 7th edition; and (3) underwent treatment with IMRT using helical tomotherapy (Accuray Inc., Sunnyvale, CA, USA).

All patients underwent a complete medical history taking and physical examination at the time of diagnosis. Fiberoptic nasopharyngoscopy, complete blood count (CBC), and baseline blood chemistry were also performed. Neck CT and/or neck magnetic resonance imaging (MRI), chest radiography with chest CT, abdominal CT, a bone scan, and PET/CT were performed for staging evaluation.

We reviewed the medical records and diagnostic images of all patients, and investigated prognostic factors including SUV~max~. All patients were re-staged according to the 7th edition of the AJCC. We reviewed neck MRI or neck CT (if neck MRI was not performed) for evaluating the node size of patients with LN metastasis, and evaluated the longest diameter of the coronal (long axis) and axial scan (short axis) for the largest metastatic nodes. Nodal size was evaluated in 40 patients, excluding 6 patients whose initial imaging was insufficient. We retrospectively reviewed the initial PET/CT of all patients and the pre-treatment SUV~max~ of the primary nasopharyngeal lesion and metastatic nodes. The pre-treatment SUV~max~ of the primary site was identified for all 53 patients. Because 7 patients did not have any metastatic lymph nodes (N0) or did not have a numerical value of the SUV~max~ of metastatic LNs recorded, pre-treatment nodal SUV~max~ was identified for 46 patients. For patients with multiple metastatic nodes, the highest SUV~max~ value among several nodal lesions was selected as the nodal SUV~max~. We also reviewed PET/CT performed within 3 months after completion of RT, and we examined the post-RT metabolic response in 26 patients.

2. Protocol of PET/CT and imaging analysis
------------------------------------------

All patients underwent PET/CT before treatment. Both institutions used the same PET/CT protocol (fasting duration, pre-injected blood glucose level, amount of injected ^18^F-FDG, post-injection interval), but the PET/CT scanner used was different---one institution used Biograph Duo (Siemens Medical Solutions, Knoxville, TN, USA) and the other institution used Discovery STE (GE Healthcare Inc., Milwaukee, WI, USA). Subjects fasted for at least 6 hours before PET/CT scans, and their blood glucose levels were measured before injection of ^18^F-FDG. None of the patients had blood glucose levels greater than 130 mg/dL before injection. A dose of 5.5--7.4 MBq/kg of FDG was administered intravenously and scanning began 60 minutes after injection. The CT scan began at the orbitomeatal line and progressed to the proximal thigh (Biograph Duo: 130 kVp, 80 mA, and 5 mm slice thickness; Discovery STE: 140 kVp, auto mA, and 3.75 mm slice thickness). The PET scan followed immediately over the same body region. The CT data were used for attenuation correction, and images were reconstructed using a standard ordered-subset expectation maximization (OSEM) algorithm (2 iterations, 8 subsets). The axial resolution was 6.5 or 4.5 mm at the center of the field of view.

All PET/CT images were analyzed by experienced nuclear medicine physicians. The metabolic activity of any lesion with a visually abnormal FDG uptake was analyzed using the standardized uptake value (SUV). SUV was calculated by the following formula:
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SUV~max~ of ^18^F-FDG was measured by visually placing the region of interest (ROI) around the site of increased FDG uptake.

3. Radiotherapy
---------------

For simulation and treatment, patients were placed in the supine position and immobilized from head to neck with a thermoplastic mask (CIVCO Radiotherapy Inc., Coralville, IA, USA). A CT simulation was performed with a slice thickness of 2.5 mm extending from the vertex to the upper chest using a LightSpeed RT 16 CT scanner (GE Healthcare Inc.). All patients were treated with IMRT with a radical aim with a 6-MV photon beam using helical tomotherapy, 5 days per week. Gross tumor volume (GTV) was delineated based on enhanced neck CT, neck MRI, and PET/CT. IMRT was performed by using a simultaneous integrated boost technique for each GTV of the nasopharynx and metastatic nodes, and clinical target volume (CTV) 1, 2, and 3. CTV1 was defined as the GTV of the nasopharynx plus a 5-mm to 1-cm margin to cover the risky sites of microscopic tumor cell infiltration around the GTV and anatomic extension of the nasopharynx. CTV2 was defined as the high-risk region of lymph node metastasis (both II, III, and Va), and CTV3 was defined as the low-risk region of lymph node metastasis (both IV and Vb). The planning target volume (PTV) was defined as the 3--5 mm margin of each CTV. The prescription dosage was 68--76 Gy/32--36 fractions (fraction size, 2.12--2.3 Gy) to the GTV of the primary site and metastatic nodes, respectively, 60--66 Gy/32--36 fractions (fraction size, 1.8--2 Gy) to CTV1, 57--61 Gy/32--36 fractions (fraction size, 1.7--1.9 Gy) to CTV2, and 50--56 Gy/24--36 fractions (fraction size, 1.6--2.12 Gy) to CTV3. For CTV3, some patients were scheduled for 50.8 Gy/24 fractions (fraction size, 2.12 Gy) or 50 Gy/25 fractions (fraction size, 2.0 Gy) and were excluded from the target volume in a cone down plan. The prescription dose of PTV was 80%--100% of the dose to each CTV. The prescribed dose encompassed at least 95% of the target volume. Critical adjacent structures such as the brainstem, optic nerve, optic chiasm, parotid gland, submandibular gland, and mandible were spared as much as possible so as not to exceed the tolerance dose.

4. Chemotherapy
---------------

All patients except for one (who was treated with definitive radiotherapy alone) were treated with concurrent chemoradiation therapy (CCRT). Among these, 14 patients were treated with CCRT alone, 4 patients underwent neoadjuvant chemotherapy, 32 patients underwent adjuvant chemotherapy, and 2 patients underwent both neoadjuvant and adjuvant chemotherapy. Forty-eight out of 52 patients were treated with a cisplatin-based regimen (cisplatin 30 mg/m^2^ on day 1 and every week for 6 or 7 cycles or cisplatin 100 mg/m^2^ on day 1 and then every 3 weeks for 3 or 4 cycles during radiotherapy). The other four patients were administered either cisplatin (100 mg/m^2^)/5-fluorouracil (5-FU; 1,000 mg/m^2^), carboplatin (30 mg/m^2^), etoposide (120 mg/m^2^)/cisplatin (60 mg/m^2^), or cetuximab, respectively. Cisplatin (100 mg/m^2^ on day 1)/5-FU (1,000 mg/m^2^ on days 1--5) was administered every month for 3 or 4 cycles, and docetaxel (70 mg/m^2^ on day 1)/cisplatin (70 mg/m^2^ on day 1)/5-FU (700 mg/m^2^ on days 1--4) were administered every 3 weeks for 2 or 3 cycles, as induction or adjuvant chemotherapy.

5. Patient assessments and follow-up
------------------------------------

All patients were evaluated weekly during RT, and then they underwent follow-up every 2--3 months after completion of RT for the first 2 years and every 4--6 months after that. Fiberoptic nasopharyngoscopy, CBC, blood chemistry, and physical examination including neck node palpation were performed at each follow-up. Neck CT or neck MRI was performed one month after the end of RT and PET/CT was performed three months for initial therapeutic response evaluation. Initial therapeutic response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1.

6. Study endpoints and statistical analysis
-------------------------------------------

The primary endpoint of this study was the prognostic value of the SUV~max~ of PET/CT for treatment outcomes. Secondary end points were overall survival (OS), disease-free survival (DFS), locoregional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS). We analyzed survival, recurrence, and prognostic factors including SUV~max~ of PET/CT. All statistical analysis was performed using SPSS ver. 18 for Windows, (SPSS Inc., Chicago, IL, USA). Actuarial 3-year OS, DFS, LRRFS, and DMFS were analyzed by the Kaplan-Meier method and the correlation of the survival rates with prognostic factors was analyzed by the log-lank test. Multivariate Cox proportional hazard models for OS and DFS were built with prognostic factors with a p-value of \<0.1 in univariate analysis. A p-value less than 0.05 was defined as statistically significant. Chi-square tests and independent-sample t-tests were used to compare characteristics between the two groups classified by the cut-off of 13.4 for SUV~max~-n. The correlation between primary site SUV~max~ and nodal SUV~max~, and the correlation between nodal size and nodal SUV~max~ were analyzed by linear regression. OS, DFS, LRRFS, and DMFS were calculated from the first date of treatment to the date of an event or the last follow-up visit. The endpoint of OS was defined as the occurrence of any death or last follow-up visit and the endpoint of DFS was defined as the occurrence of disease-related death or the diagnosis of a recurrence.

Results
=======

1. Patient characteristics and clinical outcomes
------------------------------------------------

A total of 53 patients who underwent IMRT between October 2006 and April 2016 were analyzed. The median age of this group was 49 years (range, 14 to 75 years) and the majority was men (79.2%). Thirty-nine patients (73.6%) out of 53 patients were positive for Epstein-Barr virus (EBV). Their pathologic classification was based on the 2005 World Health Organization classification. However, when the tissue type was described only as poorly differentiated nasopharyngeal carcinoma, it was categorized as 'poorly differentiated carcinoma,' and when the tissue type was described only as a nasopharyngeal carcinoma; it was categorized as 'unclassified'. The most common pathologic type was non--keratinizing carcinoma (42 patients, 79.2%). Most of the patients (79.2%) had an advanced stage (stage III--IVB) and all patients had a performance status below Eastern Cooperative Oncology Group performance status 2. The patient characteristics are summarized in [Table 1](#t1-roj-2017-00115){ref-type="table"}. Comparative assessment of the patients' characteristics between the two groups based on the nodal SUV~max~ cut-off value of 13.4 did not demonstrate any significant differences ([Table 2](#t2-roj-2017-00115){ref-type="table"}). The median nodal size of the largest metastatic LN for the long axis was 31 mm (range, 12 to 59.04 mm) and 26 mm (range, 14 to 48.7 mm) for the short axis in the total cohort.

The median follow-up duration was 31.5 months (range, 3.4 to 98.7 months). Eight patients died and 8 patients experienced a recurrence during the follow-up period. Among the patients who experienced a recurrence, there was 1 patient with an isolated local recurrence, 2 patients with a distant recurrence without locoregional recurrence, 3 patients with local and regional recurrences, 1 patient with regional and distant recurrence, and 1 patient with local, regional, and distant recurrences. Recurrence or progression in the lymph node was categorized as a regional recurrence regardless of the presence of lymph node metastasis at initial diagnosis.

Three-year OS, DFS, LRRFS, and DMFS rates were 83.2%, 77.5%, 85.4%, and 90.9%, respectively. There were 28 patients (52.8%) with a complete response, 21 (39.6%) with a partial response, 2 with stable disease, and no patients with progressive disease at initial therapeutic response evaluation. The post-RT metabolic response was evaluated in 26 patients who underwent PET/CT within 3 months after completion of RT. Twelve patients had a metabolic complete response (SUV~max~ ≤ 2.5), and 14 patients had a metabolic partial response (SUV~max~ \> 2.5); no patients had metabolic stable disease or progressive disease.

2. SUV~max~ value of primary site and metastatic node and interaction
---------------------------------------------------------------------

The pre-treatment SUV~max~ of the primary site and metastatic lymph node were investigated and were named 'SUV~max~-p' and 'SUV~max~-n', respectively. The median SUV~max~-p was 11.4 (range, 4.1 to 23.4) and the median SUV~max~-n was 9.8 (range, 2.3 to 24.5) in our cohort. The best cut-off value of the SUV~max~-p and SUV~max~-n was 13.2 (area under the curve \[AUC\], 0.812; p = 0.010) and 13.4 (AUC, 0.976; p \< 0.001) by receiver operating characteristic (ROC) curve analysis for recurrence ([Fig. 1](#f1-roj-2017-00115){ref-type="fig"}). When we analyzed the association between SUV~max~-p and SUV~max~-n by linear regression, a weak correlation was found between them (R^2^ = 0.144, p = 0.010, data not shown). In addition, the node size of the short axis and SUV~max~-n showed no significant correlation (R^2^ = 0.118, p = 0.103), while the node size of the long axis and SUV~max~-n showed a weak correlation (R^2^ = 0.106, p = 0.043).

3. Prognostic significance of SUV~max~ on survival and recurrence
-----------------------------------------------------------------

In univariate analysis, pathology, high SUV~max~-p (≥13.2), and high SUV~max~-n (≥13.4) were significant prognostic factors ([Table 3](#t3-roj-2017-00115){ref-type="table"}). The non-keratinizing (differentiated and undifferentiated) nasopharyngeal carcinoma pathology group had a significantly higher OS (p = 0.006), DFS (p = 0.017), and LRRFS (p \< 0.001) at 3 years than the keratinizing squamous cell carcinoma pathology group. The higher SUV~max~-p (≥13.2) group had a significantly lower DFS (p = 0.023) than the lower SUV~max~-p group (\<13.2). A higher SUV~max~-n (≥13.4) was a negative prognostic factor for 3-year OS (93.1% vs. 55.5%; p = 0.003) as well as for DFS (92.7% vs. 38.5%; p \< 0.001), LRRFS (100% vs. 50.5%; p \< 0.001), and DMFS (100% vs. 69.2%; p = 0.004) ([Fig. 2](#f2-roj-2017-00115){ref-type="fig"}). There was no statistically significant difference between the two groups when classified by median value of largest nodal size. Additionally, a metabolic complete response response did not demonstrate significant results for survival and recurrence in univariate analysis. In multivariate analysis, only a high SUV~max~-n (≥13.4) was statistically significant. A high SUV~max~-n (≥13.4) was a negative and independent prognostic factor for OS (hazard ratio \[HR\], 7.799; 95% confidence interval \[CI\], 1.506--40.397; p = 0.014) as well as for DFS (HR, 9.392; 95% CI, 1.989--44.339; p = 0.005) ([Table 4](#t4-roj-2017-00115){ref-type="table"}).

Discussion and Conclusion
=========================

Identifying prognostic factors for individualized therapy in patients with nasopharyngeal carcinoma is currently a major issue, and several studies have been conducted on risk stratification of patients using EBV DNA level and PET/CT parameters \[[@b16-roj-2017-00115]-[@b20-roj-2017-00115]\]. Several previous studies have suggested pre treatment SUV~max~ has prognostic value for nasopharyngeal cancer, as shown in [Table 5](#t5-roj-2017-00115){ref-type="table"} \[[@b9-roj-2017-00115]-[@b15-roj-2017-00115]\], but for most of these studies, only the SUV~max~ of the primary site was analyzed. This study focused on the importance of both the nodal and primary site SUV~max~, and we found that nodal SUV~max~ is an independent prognostic factor for OS and DFS. This is consistent with a previous study by Chan et al. \[[@b13-roj-2017-00115]\], in which a higher nodal SUV~max~ (≥6.5) was a negative prognostic factor for DFS (HR, 4.1; 95% CI, 1.045--16.084; p=0.043) in nasopharyngeal cancer patients. In addition, in a study of 178 patients with head and neck squamous cell carcinoma, that included 28 patients with nasopharyngeal carcinoma, the higher nodal SUV~max~ (≥6) group had a significantly lower DFS rate (HR, 1.81; 95% CI, 1.02--3.23; p = 0.04) and a DMFS rate (HR, 3.34; 95% CI, 1.25--8.92; p = 0.016). In addition, nodal SUV~max~ was found to be a stronger prognostic factor than SUV~max~ of the primary site \[[@b21-roj-2017-00115]\].

In our univariate analysis, SUV~max~-n was found to be a significant factor for LRRFS (100% vs. 50.5%; p \< 0.001) and DMFS (100% vs. 69.2%; p = 0.004). However, multivariate analysis for SUV~max~-n was not performed for LRRFS and DMFS because both locoregional recurrence and distant metastasis only occurred in the higher SUV~max~-n group. Therefore, further information about the relationships between SUV~max~-n and locoregional recurrence and distant metastasis can be achieved through further study.

Additionally in the univariate analysis, we found the early AJCC stage group (I--II) had a lower DMFS than the advanced stage group (III--IVB). Because early AJCC stage was only observed in one out of 4 patients with distant metastasis, we thought this likely to be a bias caused by the small sample size.

In this study, we did not find any significance of post-RT metabolic response on patients' survival and recurrence. However, there is a previous study in which a post-treatment metabolic complete response state was found to be a favorable factor for overall survival and DFS \[[@b11-roj-2017-00115]\]. And, because of the limited number of patients, further studies with more patients will be needed.

We did not find an independent association of primary SUV~max~ with survival and disease progression. When we analyzed the correlation between primary SUV~max~ and nodal SUV~max~, only a weak correlation (R^2^ = 0.144, p = 0.010) was found. Therefore, nodal SUV~max~ is a prognostic factor that provides more significant information about the patient's clinical outcome than the primary SUV~max~. In addition, only the long axis nodal size showed a weak correlation with SUV~max~-n (R2 = 0.106, p = 0.043), unlike the short axis node size. This suggests that nodal SUV~max~ is a factor that reflects biologic aggressiveness of nodal metastasis and can predict the prognosis of patients independently of node size.

In this study, we used a relatively high cut-off value (SUV~max~-p, 13.2; SUV~max~-n, 13.4) compared with previous studies on SUV~max~ in nasopharyngeal carcinoma. Compared with other studies, the median SUV~max~ itself was relatively higher, as shown in [Table 5](#t5-roj-2017-00115){ref-type="table"} \[[@b9-roj-2017-00115]-[@b15-roj-2017-00115]\]. This may be because of the measuring protocol and device used, and may be a reflection of the tumor burden, because 80% of the study objects were in an advanced stage.

This study has several limitations. First, as a retrospective study, there could be a selection bias for treatment strategy and chemotherapy that was performed heterogeneously among patients. Second, it includes a relatively low number of patients and few events. Third, there may have been few inconsistencies in the SUV~max~ because two different PET scanners were used, although they used the same protocol. In general, SUV measurements may vary from institution to institution depending on the differences in PET/CT protocols, PET/CT scanners, and imaging analysis methods. This imposes limitations on reproducibility. Because of these limitations, the optimal cut-off value of this study may not consistently be the best discrimination value in other patient groups. In addition, SUV~max~ has a limitation in that it does not reflect the heterogeneity of the total tumor lesion and volume.

To overcome these limitations, studies using prognostic factors such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of PET/CT have recently been proposed. Yoon et al. \[[@b22-roj-2017-00115]\] reported high MTV (≥31.45 cm^3^ if set to cut-off 2.5; ≥23.01 cm^3^ if set to cut-off 3.0) was a negative prognostic factor for OS (HR, 3.7019; 95% CI, 0.4746--9.3602; p = 0.0453 and HR, 5.1274; 95% CI, 1.1594--15.6541; p = 0.0198) in nasopharyngeal cancer patients. The TLG is the value obtained by multiplying the SUVmean by MTV; it reflects the volumetric factor as well as biologic activity of the whole tumor. In a study by Chan et al. \[[@b19-roj-2017-00115]\] high TLG (\>330) was found to be a negative prognostic factor for OS (HR, 1.0013; 95% CI, 1.0005--1.0021; p = 0.0014) and DFS (HR, 3.0263; 95% CI, 1.6307--5.6164; p = 0.0005). Theoretically, TLG reflects the disease activity of the entire tumor lesion and its volume factor may be superior to SUV~max~ or MTV in prognostication, but this has not yet been proven \[[@b20-roj-2017-00115],[@b23-roj-2017-00115],[@b24-roj-2017-00115]\]. In a recent meta-analysis of ^18^F-FDG-PET/CT in nasopharyngeal carcinoma by Lin et al. \[[@b25-roj-2017-00115]\] SUV, MTV, and TLG were found to be significant prognostic factors for OS and event-free survival, respectively. Although MTV and TLG were not analyzed in this study, the prognostic significance of SUV~max~ has been demonstrated several times in previous studies \[[@b9-roj-2017-00115]-[@b15-roj-2017-00115]\]. The results of this study were meaningful in suggesting the importance of nodal SUV~max~, unlike previous studies focusing on primary tumors.

In conclusion, high pre-treatment nodal SUV~max~ was an independent prognosticator of survival and disease progression in nasopharyngeal carcinoma patients treated with IMRT in our cohort. Therefore, it may provide important information for identifying patients who require more aggressive treatment.
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![Receiver operating characterstic (ROC) curve of SUV~max~ of the primary site and metastatic node for predicting recurrence. The best cut-off values for SUV~max~-p and SUV~max~-n depicted by the ROC curve were 13.2 and 13.4 for recurrence. SUV~max~, maximum standardized uptake value; SUV~max~-p, pretreatment SUV~max~ of primary site; SUV~max~-n, pretreatment SUV~max~ of metastatic nodes.](roj-2017-00115f1){#f1-roj-2017-00115}

![Kaplan-Meier estimates of survival curves for the SUV~max~-n \< 13.4 and SUV~max~-n ≥ 13.4 groups. (A) Overall survival (OS) of two groups (93.1% vs. 55.5%; p = 0.003). (B) Disease-free survival (DFS) of two groups (92.7% vs. 38.5%; p \< 0.001). (C) Locoregional recurrence-free survival (LRRFS) of two groups (100% vs. 50.5%; p \< 0.001). (D) Distant metastasis-free survival (DMFS) of two groups (100% vs. 69.2%; p = 0.004).](roj-2017-00115f2){#f2-roj-2017-00115}

###### 

Clinical characteristics of patients (n = 53)

  characteristic            No. of patients (%)
  ------------------------- ---------------------
  Sex                       
   Male                     42 (79.2)
   Female                   11 (20.8)
  Age (yr)                  
   \<49                     26 (49.1)
   ≥49                      27 (50.9)
  EBV status                
   (−)                      4 (7.5)
   (+)                      39 (73.6)
   Unknown                  10 (18.9)
  ECOG performance status   
   0                        31 (58.5)
   1                        21 (39.6)
   2                        1 (1.9)
  Pathology                 
   Keratinizing             5 (9.4)
   Non-keratinizing         42 (79.2)
   Poorly differentiated    4 (7.6)
   Unclassified             2 (3.8)
  T stage                   
   T1--T2                   29 (54.7)
   T3--T4                   24 (45.3)
  N stage                   
   N0                       7 (13.2)
   N1--N2                   40 (75.5)
   N3                       6 (11.3)
  AJCC stage                
   I--II                    11 (20.8)
   III--IVB                 42 (79.2)
  Treatment                 
   CCRT alone               14 (26.4)
   NCT + CCRT               4 (7.5)
   CCRT + ACT               32 (60.4)
   NCT + CCRT + ACT         2 (3.8)
   RT alone                 1 (1.9)

EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group; Keratinizing, keratinizing squamous cell nasopharyngeal carcinoma; Non-keratinizing, non keratinizing nasopharyngeal carcinoma; Poorly differentiated, poorly differentiated nasopharyngeal carcinoma; AJCC, American Joint Committee on Cancer; CCRT, concurrent chemoradiation therapy; NCT, neoadjuvant chemotherapy; ACT, adjuvant chemotherapy; RT, radiotherapy.

###### 

Patients' characteristics according to SUV~max~-n group (n = 46)

                            SUV~max~-n \< 13.4 (n = 33)   SUV~max~-n ≥ 13.4 (n = 13)   p-value
  ------------------------- ----------------------------- ---------------------------- ---------
  Sex                                                                                  
   Male                     26 (78.8)                     11 (84.6)                    0.409
   Female                   7 (21.2)                      2 (15.4)                     
  Age (yr)                                                                             
   \<49                     21 (63.6)                     8 (61.5)                     1
   ≥49                      12 (36.4)                     5 (38.5)                     
  EBV status                                                                           
   (−)                      3 (9.1)                       0 (0)                        0.562
   (+)                      25 (75.8)                     9 (69.2)                     
  ECOG performance status                                                              
   0                        18 (54.5)                     9 (69.2)                     0.154
   1                        15 (45.5)                     3 (23.1)                     
   2                        0 (0)                         1 (7.7)                      
  Pathology                                                                            
   Keratinizing             1 (3)                         3 (23)                       0.138
   Non-keratinizing         27 (81.8)                     9 (69.2)                     
   Poorly differentiated    3 (9.1)                       1 (7.7)                      
  T stage                                                                              
   T1--T2                   17 (51.5)                     10 (76.9)                    0.115
   T3--T4                   16 (48.5)                     3 (23.1)                     
  N stage                                                                              
   N0--N1                   11 (33.3)                     4 (30.8)                     1
   N2--N3                   22 (66.7)                     9 (69.2)                     
  AJCC stage                                                                           
   I--II                    6 (18.2)                      3 (23.1)                     0.698
   III--IVB                 27 (81.8)                     10 (76.9)                    
  Treatment                                                                            
   CCRT                     10 (30.3)                     2 (15.4)                     0.684
   NCT + CCRT               3 (9.1)                       1 (7.7)                      
   CCRT + ACT               19 (57.6)                     9 (69.2)                     
   NCT + CCRT + ACT         1 (3.0)                       1 (7.7)                      
  Node size (mm)                                                                       
   Long axis                30.889                        35.012                       0.231
   Short axis               26.333                        28.069                       0.528

Values are presented as number (%).

EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group; Keratinizing, keratinizing squamous cell nasopharyngeal carcinoma; Non-keratinizing, non keratinizing nasopharyngeal carcinoma; Poorly differentiated, poorly differentiated nasopharyngeal carcinoma; AJCC, American Joint Committee on Cancer; CCRT, concurrent chemoradiation therapy; NCT, neoadjuvant chemotherapy; ACT, adjuvant chemotherapy.

###### 

Univariate analysis of prognostic factors

                      No. of patients   3-yr OS   3-yr DFS                                                 3-yr LRRFS   3-yr DMFS                                                                                                                           
  ------------------- ----------------- --------- -------------------------------------------------------- ------------ ---------------------------------------------------------- ------ ---------------------------------------------------------- ------ --------------------------------------------------------
  Sex                                                                                                                                                                                                                                                       
   Male               42                78.8      0.123                                                    74.1         0.353                                                      81.3   0.177                                                      90.9   0.897
   Female             11                100                                                                90.0                                                                    100                                                               90.0   
  Age (yr)                                                                                                                                                                                                                                                  
   \<49               26                90.2      0.377                                                    80.8         0.587                                                      85.0   0.989                                                      91.3   0.913
   ≥49                27                76.2                                                               74.5                                                                    85.7                                                              90.7   
  T stage                                                                                                                                                                                                                                                   
   T1--T2             29                82.6      0.847                                                    80.0         0.824                                                      88.1   0.817                                                      83.7   0.067
   T3--T4             24                84.1                                                               74.6                                                                    81.9                                                              100    
  N stage                                                                                                                                                                                                                                                   
   N0--N1             21                93.8      0.098                                                    88.8         0.195                                                      88.8   0.728                                                      93.8   0.527
   N2--N3             32                76.0                                                               70.2                                                                    82.5                                                              89.1   
  AJCC stage                                                                                                                                                                                                                                                
   I--II              11                87.5      0.510                                                    90.0         0.402                                                      90.0   0.807                                                      87.5   0.870
   III--IVB           42                81.5                                                               74.3                                                                    84.1                                                              91.5   
  EBV                                                                                                                                                                                                                                                       
   (−)                4                 100       0.872                                                    75.0         0.887                                                      75.0   0.486                                                      100    0.525
   (+)                39                85.3                                                               81.2                                                                    89.8                                                              90.2   
  Pathology                                                                                                                                                                                                                                                 
   Keratinizing       5                 50.0      0.006^[\*](#tfn1-roj-2017-00115){ref-type="table-fn"}^   25.0         0.017^[\*](#tfn1-roj-2017-00115){ref-type="table-fn"}^     25.0   \<0.001^[\*](#tfn1-roj-2017-00115){ref-type="table-fn"}^   75.0   0.243
   Non-keratinizing   42                84.6                                                               80.5                                                                    90.8                                                              91.2   
  Treatment                                                                                                                                                                                                                                                 
   CCRT               14                61.1      0.124                                                    57.7         0.158                                                      85.7   0.659                                                      85.7   0.822
   NCT + CCRT         4                 66.7                                                               66.7                                                                    66.7                                                              100    
   CCRT + ACT         32                89.3                                                               83.7                                                                    86.7                                                              90.3   
  SUV~max~-p                                                                                                                                                                                                                                                
   \<13.2             32                89.4      0.104                                                    89.4         0.023^[\*](#tfn1-roj-2017-00115){ref-type="table-fn"}^     92.6   0.101                                                      96.4   0.140
   ≥13.2              21                71.5                                                               56.1                                                                    69.8                                                              82.1   
  SUV~max~-n                                                                                                                                                                                                                                                
   \<13.4             33                93.1      0.003^[\*](#tfn1-roj-2017-00115){ref-type="table-fn"}^   92.7         \<0.001^[\*](#tfn1-roj-2017-00115){ref-type="table-fn"}^   100    \<0.001^[\*](#tfn1-roj-2017-00115){ref-type="table-fn"}^   100    0.004^[\*](#tfn1-roj-2017-00115){ref-type="table-fn"}^
   ≥13.4              13                55.5                                                               38.5                                                                    50.5                                                              69.2   
  Node size (mm)                                                                                                                                                                                                                                            
   Long axis                                                                                                                                                                                                                                                
    \<31              20                89.1      0.360                                                    89.1         0.185                                                      95.0   0.495                                                      89.7   0.645
    ≥31               20                74.3                                                               71.7                                                                    86.2                                                              94.4   
   Short axis                                                                                                                                                                                                                                               
    \<26.5                              84.5      0.816                                                    81.3         0.948                                                      90.9   0.966                                                      80.5   0.046
    ≥26.5                               79.8                                                               80.4                                                                    88.9                                                              100    

OS, overall survival; DFS, disease-free survival; LRRFS, locoregional recurrence-free survival; RRFS, regional recurrence-free survival; DMFS, distant metastasis-free survival; AJCC, American Joint Committee on Cancer; EBV, Epstein-Barr virus; Keratinizing, keratinizing squamous nasopharyngeal carcinoma; Non-keratinizing, non-keratinizing nasopharyngeal carcinoma; CCRT, concurrent chemoradiation therapy; NCT, neoadjuvant chemotherapy; ACT, adjuvant chemotherapy; SUV~max~-p, pretreatment SUV~max~ of primary site; SUV~max~-n, pretreatment SUV~max~ of metastatic nodes.

p \< 0.05.

###### 

Multivariate analysis of prognostic factors

                                                   HR (95% CI)             p-value
  ------------------------------------------------ ----------------------- ---------
  3-yr OS                                                                  
   Pathology (keratinizing vs. non-keratinizing)   0.370 (0.070--1.943)    0.240
   SUV~max~-n (\<13.4 vs. ≥13.4)                   7.799 (1.506--40.397)   0.014
  3-yr DFS                                                                 
   Pathology (keratinizing vs. non-keratinizing)   0.439 (0.106--1.827)    0.258
   SUV~max~-p (\<13.2 vs. ≥13.2)                   1.981 (0.467--8.399)    0.354
   SUV~max~-n (\<13.4 vs. ≥13.4)                   9.392 (1.989--44.339)   0.005

HR, hazard ratio; CI, confidence interval; OS, overall survival; DFS, disease-free survival; Keratinizing, keratinizing squamous nasopharyngeal carcinoma; Non-keratinizing, non-keratinizing nasopharyngeal carcinoma; SUV~max~-p, pretreatment SUV~max~ of primary site; SUV~max~-n, pretreatment SUV~max~ of metastatic nodes.

###### 

Other studies of SUV~max~ in nasopharyngeal cancer

  Study                                    Stage      SUV~max~             SUV~max~ cut-off   p-value                                                                                                                                                            
  ---------------------------------------- ---------- -------------------- ------------------ --------- ------ ------ -------------------------------------------------------- ------- --------------------------------------------------------- ------- ------- --------------------------------------------------------
  Lee et al. \[[@b9-roj-2017-00115]\]      I--IVB     6.48 (2.3--26.0)     \-                 8         \-            NA                                                       \-      0.043                                                     \-      NA      \-
  Chan et al. \[[@b10-roj-2017-00115]\]    I--IVB     \-                   \-                 12        \-     \-     NS                                                       \-      NS                                                        \-      0.012   \-
  Xie et al. \[[@b11-roj-2017-00115]\]     III--IVB   8.55 (2.8--24.6)     \-                 8         \-     \-     0.019^[\*](#tfn2-roj-2017-00115){ref-type="table-fn"}^   \-      0.0163^[\*](#tfn2-roj-2017-00115){ref-type="table-fn"}^   \-      NA      \-
  Liu et al. \[[@b12-roj-2017-00115]\]     I--IVB     4.9 (2.7--15.5)      \-                 5         \-     \-     0.065                                                    \-      \<0.001                                                   \-      NA      \-
  Chan et al. \[[@b13-roj-2017-00115]\]    I--IV      7.8 (2.6--21.3)      6.9 (1.5--20.9)    7.5       6.5    \-     NA                                                       NA      0.025                                                     0.043   NA      NA
  Xiao et al. \[[@b14-roj-2017-00115]\]    I--IVB     10.23 (2.7--33.10)   \-                 10.2      \-     \-     0.004                                                    \-      NA                                                        \-      0.002   \-
  Jeong et al. \[[@b15-roj-2017-00115]\]   II--IVB    8.2 (2.2--25.8)      8.0 (1.6--19.6)    8         \-     10.6   NA                                                       NA      NA                                                        NA      0.033   0.001
  This study                               I--IVB     11.4 (4.1--23.4)     9.8 (2.3--24.5)    13.2      13.4   \-     NS                                                       0.014   0.023^[\*](#tfn2-roj-2017-00115){ref-type="table-fn"}^    0.005   NS      0.004^[\*](#tfn2-roj-2017-00115){ref-type="table-fn"}^

Values are presented as median (range) or number.

SUV~max~, maximum standardized uptake value; OS, overall survival; DFS, disease free-survival; DMFS, distant metastasis-free survival; P, primary site; N, metastatic node; N(f), farthest metastatic lymph node; NA, no analysis; NS, no significance.

p-value was significant only in univariate analysis.
